Zhitong Financial APP News, Zetong Pharmaceutical (688266.SH) announced that the company recently received a "notice of approval for Drug Clinical Trials" approved and issued by the State Drug Administration (hereinafter referred to as "SDA"). The clinical trial of ZG19018 tablets in the treatment of advanced malignant solid tumors with KRAS G12C mutation was approved.

It is reported that the approval of the clinical trial of ZG19018 tablets in the treatment of advanced malignant solid tumors with KRAS G12C mutations will not have a significant impact on the company's short-term performance. ZG19018 is a selective covalent inhibitor of KRAS G12C independently developed by the company, which belongs to class 1 small molecule anti-tumor drugs and has global intellectual property rights.